AExcellent

Biogen Inc.(BIIB)

A

Financial data as of Dec 31, 2025Declining · Healthcare

FCF Margin19.9%Free Cash Flow / Revenue
Cash Conversion170.5%Operating CF / Net Income
Free Cash Flow$2.0B
Revenue$9.9B
Net Cash-$3.6BNet debt position
Debt / FCF3.3xElevated debt burden
Current Ratio2.68Adequate short-term liquidity
YoY FCF Growth-42.2%5 of 5 quarters positive

How This Grade Was Calculated

Base grade from FCF margin, adjusted by financial health factors

BaseA
+0.5Healthy FCF margin with manageable debt (19.9%, 3.3x)
-1Significant YoY FCF decline (-42.2%)
FinalA

Analysis Summary

Strengths

  • Strong FCF margin (19.9%)
  • Excellent cash conversion (171%)
  • Strong liquidity (current ratio: 2.68)

Concerns

  • Net debt position ($3.6B)
  • Significant YoY FCF decline (-42.2%)
  • Significant FCF decline (-42.2% YoY)

Financial Breakdown

Key financials compared side by side

Margin Composition

FCF Margin19.9%
Net Margin13.1%
Operating CF Margin22.3%
CapEx Ratio2.4%

Balance Sheet Health

Debt, liquidity, and leverage snapshot

Net Cash-$3.6BNet debt position
Debt / FCF3.3xElevated debt burden
Current Ratio2.68Strong liquidity
Debt / Equity0.36Low leverage

Quarterly FCF Trend

-42.2% YoYDeclining (-42.2%)

Free cash flow per quarter

Sector Comparison — Healthcare

FCF Margin ranked against sector peers

View all →

Detailed Metrics

Company NameBiogen Inc.
SectorHealthcare
Free Cash Flow$2.0B
Revenue$9.9B
Net Income$1.3B
Operating Cash Flow$2.2B
Capital Expenditure$235.4M
FCF Margin19.9%
Cash Conversion Rate170.5%
Net Margin13.1%
Total Debt$6.6B
Total Cash$3.0B
Net Cash-$3.6B
Current Ratio2.68
Debt / Equity0.36
Debt / FCF3.3x
YoY FCF Growth-42.2%
Positive Quarters5 of 5
Trend DirectionDeclining
Report DateDec 31, 2025
GradeA
Data SourceYahoo Finance